Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/27/2025

Management of Tizanidine-Induced Transaminitis

Severity-Based Management Algorithm

  • Discontinue tizanidine immediately in patients with Grade 1 Transaminitis (ALT/AST >ULN to 3× ULN) and monitor liver function tests 1-2 times weekly until normalization, as recommended by Praxis Medical Insights 1
  • Discontinue tizanidine immediately in patients with Grade 2 Transaminitis (ALT/AST >3× to 5× ULN), increase monitoring frequency to every 3 days, and evaluate for concurrent hepatotoxic medications, as recommended by Praxis Medical Insights 1
  • Discontinue tizanidine permanently in patients with Grade 3 Transaminitis (ALT/AST >5× to 20× ULN), obtain urgent hepatology consultation, and monitor for signs of acute liver failure, as recommended by Praxis Medical Insights 1
  • Hospitalize patients with Grade 4 Transaminitis (ALT/AST >20× ULN) immediately, preferably at a liver center, and permanently discontinue tizanidine, as recommended by Praxis Medical Insights 1

Monitoring Requirements

  • Repeat liver function tests within 2-4 weeks after discontinuation of tizanidine and continue monitoring every 2-4 weeks until complete normalization, as recommended by Praxis Medical Insights 1
  • Reassess at 12 weeks to confirm sustained resolution of transaminitis, as recommended by Praxis Medical Insights 2

Alternative Muscle Relaxant Selection

  • Consider Baclofen as the preferred alternative for spasticity management, though it requires careful dose titration and should never be abruptly discontinued due to risk of life-threatening withdrawal, as recommended by the Mayo Clinic 5
  • Consider Cyclobenzaprine for musculoskeletal conditions, though it has anticholinergic effects and should be held on the day of any surgical procedure, as recommended by the Mayo Clinic 5
  • Avoid carisoprodol due to its abuse potential and significant withdrawal risk, as recommended by the Mayo Clinic 5

REFERENCES

1

Management of Transaminitis [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

2

Management of Fluctuating Liver Enzymes in Hepatitis A [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025